Free Newsletter
Ebola vaccines readied for first human trials
Researchers are pushing ahead with the first human trials of an ebola vaccine. Typical vaccines spark an antibody response against a threat. But with the lethal ebola, a successful vaccine has to produce T-cells to make the immune system powerful enough vanquish the virus. And a vaccine is badly needed. A successful ebola vaccine would give health workers immunity as they fight against any outbreak, which is becoming increasingly likely.
"We are seeing more and more naturally-occurring human outbreaks of this deadly disease. With worldwide air travel and tourism, the virus can now be transported to and from remote regions of the world. And it has huge potential as a possible weapon of bioterrorism. We desperately need a protective vaccine," says Dr. Anthony Sanchez, of the U.S. Centers for Disease Control and Prevention.
- read the article in the Washington Post
Related Articles:
People, rainfall, biodiversity breed new diseases. Report
Emerging infectious diseases on the rise. Report
WHO: Infectious disease a growing threat. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




